Use of CRISPR/Cas9-engineered INS-1 pancreatic   cells to define the pharmacology of dual GIPR/GLP-1R agonists

Published 2016 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Use of CRISPR/Cas9-engineered INS-1 pancreatic   cells to define the pharmacology of dual GIPR/GLP-1R agonists
Authors
Keywords
-
Journal
BIOCHEMICAL JOURNAL
Volume 473, Issue 18, Pages 2881-2891
Publisher
Portland Press Ltd.
Online
2016-07-16
DOI
10.1042/bcj20160476

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Discover Peeref hubs

Discuss science. Find collaborators. Network.

Join a conversation

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.